製剂开发外包市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测,按服务、製剂、治疗领域、地区和竞争细分
市场调查报告书
商品编码
1331418

製剂开发外包市场 - 2018-2028 年全球行业规模、份额、趋势、机会和预测,按服务、製剂、治疗领域、地区和竞争细分

Formulation Development Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Service, By Formulation, By Therapeutic Area, By Region and Competition

出版日期: | 出版商: TechSci Research | 英文 115 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

预计製剂开发外包市场在预测期内将出现令人印象深刻的增长。这可以归因于对新药的需求不断增长、专利到期以及对开发水溶性差的化合物以提高生物利用度的关注。此外,克服与开发相关的风险的需求不断增长,以及对仿製药和生物仿製药的需求不断增长,预计将在预测期内创造利润丰厚的增长。同样,製药组织越来越注重研发活动,以保持竞争力和灵活性,这是多年来推动市场增长的主要因素。 2021 年 6 月,Taylor France 发表了一篇关于使用 3D 打印来配製和开发个性化药物的论文。 2022年3月,美国国际开发署(USAID)宣布为药物开发提供1.5亿美元资金。此类倡议可能有利于市场的增长。

节约成本

成本节约是全球製剂开发外包市场增长的关键驱动力之一。製药公司面临着降低成本和提高效率的压力,外包製剂开发可以通过多种方式帮助他们实现这些目标。首先,外包製剂开发使製药公司能够避免与建设和维护设施和设备相关的资本支出,以及持续的人员配备和培训成本。

专注于核心能力。

核心能力是影响全球製剂开发外包市场增长的另一个关键因素。製药公司越来越认识到专注于核心竞争力以保持竞争力和创新的重要性。外包配方开发可以通过多种方式帮助公司实现这一目标。首先,外包製剂开发使製药公司能够专注于其核心竞争力,例如药物发现、营销和销售。通过与专门从事配方开发的 CDMO(合同开发和製造组织)合作,公司可以腾出资源投资于他们具有竞争优势的领域。这可以帮助他们更快、更高效地开发新药,并更快地将其推向市场。其次,外包製剂开发使製药公司能够获得其内部可能没有的专业知识和设施。许多 CDMO 专注于配方开发的特定领域,例如生物製剂、无菌产品或受控物质。

通过与这些专业合作伙伴合作,公司可以获得更有效地开发药物配方所需的专业知识和基础设施。第三,外包製剂开发可以帮助製药公司降低风险并提高灵活性。通过与多个 CDMO 合作,公司可以分散风险并确保他们能够获得开发药物配方所需的专业知识和基础设施,无论其具体要求如何。

药物开发的复杂性增加

药物开发是全球製剂开发外包市场增长的重要驱动力。製药行业面临着开发新药和创新药物以满足未满足的医疗需求的持续压力,外包製剂开发可以通过多种方式帮助公司加快药物开发进程。外包配方开发可以帮助製药公司缩短上市时间。通过与专门从事製剂开发的 CDMO(合同开发和製造组织)合作,公司可以获得更快速、更高效地开发药物製剂所需的专业知识和基础设施。这可以帮助他们更快地将药物推向市场并更快地占领市场份额。此外,外包製剂开发可以帮助製药公司获得专业知识和设施。

许多 CDMO 专注于配方开发的特定领域,例如生物製剂、无菌产品或受控物质。通过与这些专业合作伙伴合作,公司可以获得更有效地开发药物配方所需的专业知识和基础设施。此外,外包製剂开发可以帮助製药公司降低开发成本。通过利用 CDMO 的专业知识和基础设施,公司可以从规模经济中受益并降低总体开发成本。这可以帮助他们更有效地分配资源并投资于其他业务领域,例如药物发现、营销和销售。

快速发展的监管环境

监管环境是影响全球製剂开发外包市场增长的关键因素。製药行业受到严格的监管要求,外包製剂开发可以帮助公司更有效地满足这些要求。首先,外包製剂开发可以帮助製药公司更有效地遵守监管要求。专门从事配方开发的 CDMO(合同开发和製造组织)通常在与监管机构合作方面经验丰富,可以帮助公司应对复杂的监管环境。这可以帮助公司避免延误和代价高昂的监管错误,这些错误可能会减慢药物开发过程并增加成本。其次,外包製剂开发可以帮助製药公司获得与监管合规性相关的专业知识。许多 CDMO 拥有内部监管专家,他们可以提供监管合规指导,以及开发满足监管要求的药物配方所需的专业知识。第三,製剂开发外包可以帮助製药公司遵守不断变化的监管要求。随着法规的发展,CDMO 可以帮助公司了解最新情况并相应地调整其药物开发流程,从而降低不合规和相关处罚的风险。

对生物製剂和其他復杂製剂的需求不断增长

生物製剂和其他復杂製剂是全球製剂开发外包市场增长的重要驱动力。生物製剂和其他復杂製剂需要内部可能无法提供的专业知识和专业知识。专门从事生物製品和其他復杂配方的 CDMO(合同开发和製造组织)拥有必要的知识和专业知识来更有效地开发和製造这些产品。通过与这些专业合作伙伴合作,製药公司可以获得更高效、更有效地开发生物製剂和其他復杂製剂所需的专业知识和基础设施。此外,生物製剂和其他復杂製剂通常需要内部可能不具备的专门基础设施。专门从事生物製剂和其他復杂製剂的 CDMO 已投资开发和製造这些产品所需的基础设施,包括专用设备和设施。通过与这些专业合作伙伴合作,製药公司可以获得更高效、更具成本效益地开发生物製剂和其他復杂製剂所需的基础设施。此外,外包生物製剂和其他復杂製剂的开发可以帮助製药公司降低风险。这些制定通常涉及高度的复杂性和风险,外包开发过程可以帮助公司分散风险并确保他们能够获得必要的专业知识和基础设施。

近期发展

  • Catalent 于 2020 年推出了新的喷雾干燥套件,其中包括具有集成研磨和颗粒工程功能的 GMP 喷雾干燥器。这个新套件使康泰伦特能够提供更广泛的药物开发服务,包括喷雾干燥、微粉化和製剂开发。
  • Thermo Fisher Scientific 于 2020 年在新加坡推出了新的 CDMO 设施,其中包括配方开发、工艺开发和临床试验製造等一系列功能。该设施旨在支持亚太地区对 CDMO 服务不断增长的需求。
  • Lonza 于 2019 年在瑞士推出了新的无菌药品灌装和加工设施,其中包括无菌灌装、冻干和最终灭菌功能。新工厂扩大了 Lonza 在无菌药品製造领域的能力,并使该公司能够为客户提供更广泛的服务。

可用的定制:

根据给定的市场数据,TechSci Research 可根据公司的具体需求提供定制服务。该报告可以使用以下自定义选项:

公司信息

  • 其他市场参与者(最多五个)的详细分析和概况分析。

目录

第 1 章:产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场细分

第 2 章:研究方法

  • 研究目的
  • 基线方法
  • 主要行业合作伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章:执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章:客户之声

第 5 章:全球製剂开发外包市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按服务分类(预製剂、製剂开发)
    • 按剂型(口服、注射、外用、其他)
    • 按治疗领域(肿瘤科、传染病科、神经科、血液科、呼吸科、心血管科、皮肤科、其他)
    • 按地区(北美、欧洲、亚太地区、南美、中东和非洲)
    • 按公司划分 (2022)
  • 市场地图
    • 按服务
    • 按配方分类
    • 按治疗领域
    • 按地区

第 6 章:北美製剂开发外包市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按服务分类(预製剂、製剂开发)
    • 按剂型(口服、注射、外用、其他)
    • 按治疗领域(肿瘤科、传染病科、神经科、血液科、呼吸科、心血管科、皮肤科、其他)
    • 按国家/地区
  • 北美:国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章:欧洲製剂开发外包市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按服务分类(预製剂、製剂开发)
    • 按剂型(口服、注射、外用、其他)
    • 按治疗领域(肿瘤科、传染病科、神经科、血液科、呼吸科、心血管科、皮肤科、其他)
    • 按国家/地区
  • 欧洲:国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 8 章:亚太製剂开发外包市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按服务分类(预製剂、製剂开发)
    • 按剂型(口服、注射、外用、其他)
    • 按治疗领域(肿瘤科、传染病科、神经科、血液科、呼吸科、心血管科、皮肤科、其他)
    • 按国家/地区
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 9 章:南美製剂开发外包市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按服务分类(预製剂、製剂开发)
    • 按剂型(口服、注射、外用、其他)
    • 按治疗领域(肿瘤科、传染病科、神经科、血液科、呼吸科、心血管科、皮肤科、其他)
    • 按国家/地区
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲製剂开发外包市场展望

  • 市场规模及预测
    • 按价值
  • 市场份额及预测
    • 按服务分类(预製剂、製剂开发)
    • 按剂型(口服、注射、外用、其他)
    • 按治疗领域(肿瘤科、传染病科、神经科、血液科、呼吸科、心血管科、皮肤科、其他)
    • 按国家/地区
  • MEA:国家分析
    • 南非製剂开发外包
    • 沙特阿拉伯製剂开发外包
    • 阿联酋配方开发外包

第 11 章:市场动态

  • 司机
  • 挑战

第 12 章:市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章:全球製剂开发外包市场:SWOT 分析

第 14 章:波特的五力分析

  • 行业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章:竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务(据报导)
  • 主要人员
  • SWOT分析
    • Charles River Laboratories.
    • Aizant Drug Research Solutions Private Limited.
    • Catalent Inc.
    • Laboratory Corporation of America Holdings.
    • Syngene International Ltd.
    • Irisys LLC.
    • Intertek Group PLC.
    • Piramal Pharma Solutions.
    • Qiotient Sciences Ltd.
    • Patheon Inc.
    • Emergent BioSolutions Inc
    • Lonza Group AG

第 16 章:战略建议

简介目录
Product Code: 7747

Formulation Development Outsourcing Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing demand for new drugs, patent expirations, and a focus on developing poorly water-soluble compounds to improve bioavailability. Also, the growing demand for overcoming the risk associated with development and growing demand for generics and biosimilar drugs is expected to create lucrative growth during the forecast period. Similarly, pharmaceutical organizations are increasingly focusing on their R&D activities to stay competitive and flexible, which is a major factor fueling the growth of the market over the years. In June 2021, Taylor France published a paper regarding the use of 3D printing for the formulation and development of personalized medicines. In March 2022, the United States Agency for International Development (USAID) announced USD 150 million in funding for drug development. Such initiatives are likely to benefit the market's growth.

Cost savings

Cost savings are one of the key drivers of the growth of the Global Formulation Development Outsourcing Market. Pharmaceutical companies are under pressure to reduce costs and improve efficiency, and outsourcing formulation development can help them achieve these goals in several ways. First, outsourcing formulation development allows pharmaceutical companies to avoid the capital expenditures associated with building and maintaining facilities and equipment, as well as the ongoing costs of staffing and training employees.

Instead, companies can leverage the expertise and infrastructure of CDMOs (Contract Development and Manufacturing Organizations) to develop their drug formulations. Second, outsourcing formulation development can help pharmaceutical companies to reduce their overall development costs. By working with CDMOs that specialize in formulation development, companies can benefit from economies of scale, as well as the expertise of specialized professionals. This can result in reduced development costs and faster time-to-market.

Third, outsourcing formulation development allows pharmaceutical companies to allocate their resources more effectively. By focusing on their core competencies, such as drug discovery, marketing, and sales, companies can free up resources to invest in other areas of their business. This can help companies to improve their competitive position and increase their profitability.

Focus on core competencies.

Core competencies are another key factor influencing the growth of the Global Formulation Development Outsourcing Market. Pharmaceutical companies are increasingly recognizing the importance of focusing on their core competencies to remain competitive and innovative. Outsourcing formulation development can help companies achieve this goal in several ways. First, outsourcing formulation development allows pharmaceutical companies to focus on their core competencies, such as drug discovery, marketing, and sales. By working with CDMOs (Contract Development and Manufacturing Organizations) that specialize in formulation development, companies can free up resources to invest in areas where they have a competitive advantage. This can help them to develop new drugs more quickly and efficiently and to bring them to market faster. Second, outsourcing formulation development allows pharmaceutical companies to access specialized expertise and facilities that they may not have in-house. Many CDMOs specialize in specific areas of formulation development, such as biologics, sterile products, or controlled substances.

By working with these specialized partners, companies can access the expertise and infrastructure needed to develop their drug formulations more effectively. Third, outsourcing formulation development can help pharmaceutical companies to reduce their risk and increase their flexibility. By working with multiple CDMOs, companies can spread their risk and ensure that they have access to the expertise and infrastructure needed to develop their drug formulations, regardless of their specific requirements.

Increased complexity of drug development

Drug development is a significant driver of the growth of the Global Formulation Development Outsourcing Market. The pharmaceutical industry is under constant pressure to develop new and innovative drugs to address unmet medical needs, and outsourcing formulation development can help companies accelerate the drug development process in several ways. Outsourcing formulation development can help pharmaceutical companies to reduce their time-to-market. By working with CDMOs (Contract Development and Manufacturing Organizations) that specialize in formulation development, companies can access the expertise and infrastructure needed to develop their drug formulations more quickly and efficiently. This can help them to bring their drugs to market faster and to capture market share more quickly. Also, outsourcing formulation development can help pharmaceutical companies to access specialized expertise and facilities.

Many CDMOs specialize in specific areas of formulation development, such as biologics, sterile products, or controlled substances. By working with these specialized partners, companies can access the expertise and infrastructure needed to develop their drug formulations more effectively. Additionally, outsourcing formulation development can help pharmaceutical companies to reduce their development costs. By leveraging the expertise and infrastructure of CDMOs, companies can benefit from economies of scale and reduce their overall development costs. This can help them to allocate their resources more effectively and invest in other areas of their business, such as drug discovery, marketing, and sales.

The rapidly evolving regulatory environment

The regulatory environment is a crucial factor that influences the growth of the Global Formulation Development Outsourcing Market. The pharmaceutical industry is subject to strict regulatory requirements, and outsourcing formulation development can help companies navigate these requirements more effectively. First, outsourcing formulation development can help pharmaceutical companies to comply with regulatory requirements more efficiently. CDMOs (Contract Development and Manufacturing Organizations) that specialize in formulation development are often experienced in working with regulatory bodies and can help companies navigate the complex regulatory landscape. This can help companies to avoid delays and costly regulatory mistakes, which can slow down the drug development process and increase costs. Second, outsourcing formulation development can help pharmaceutical companies to access specialized expertise related to regulatory compliance. Many CDMOs have in-house regulatory experts who can provide guidance on regulatory compliance, as well as the expertise needed to develop drug formulations that meet regulatory requirements. Third, the outsourcing of formulation development can help pharmaceutical companies to maintain compliance with changing regulatory requirements. As regulations evolve, CDMOs can help companies to stay up-to-date and adapt their drug development processes accordingly, reducing the risk of non-compliance and associated penalties.

Growing demand for biologics and other complex formulations

Biologics and other complex formulations are significant drivers of the growth of the Global Formulation Development Outsourcing Market. Biologics and other complex formulations require specialized knowledge and expertise that may not be available in-house. CDMOs (Contract Development and Manufacturing Organizations) that specialize in biologics and other complex formulations have the necessary knowledge and expertise to develop and manufacture these products more effectively. By working with these specialized partners, pharmaceutical companies can access the expertise and infrastructure needed to develop their biologics and other complex formulations more efficiently and effectively. Besides, biologics and other complex formulations often require specialized infrastructure that may not be available in-house. CDMOs that specialize in biologics and other complex formulations have invested in the infrastructure needed to develop and manufacture these products, including specialized equipment and facilities. By working with these specialized partners, pharmaceutical companies can access the infrastructure needed to develop their biologics and other complex formulations more efficiently and cost-effectively. Moreover, outsourcing the development of biologics and other complex formulations can help pharmaceutical companies to reduce their risk. These formulations often involve a high degree of complexity and risk, and outsourcing the development process can help companies to spread their risk and ensure that they have access to the necessary expertise and infrastructure.

Recent Development

  • Catalent launched a new spray drying suite in 2020, which includes a GMP spray dryer with integrated milling and particle engineering capabilities. This new suite allows Catalent to offer a wider range of drug development services, including spray drying, micronization, and formulation development.
  • Thermo Fisher Scientific launched a new CDMO facility in Singapore in 2020, which includes a range of capabilities, including formulation development, process development, and clinical trial manufacturing. The facility is designed to support the growing demand for CDMO services in the Asia-Pacific region.
  • Lonza launched a new sterile drug product fill and finish facility in Switzerland in 2019, which includes capabilities for aseptic filling, lyophilization, and terminal sterilization. The new facility expands Lonza's capabilities in the sterile drug product manufacturing space and allows the company to offer a wider range of services to its customers.

Market Segmentation

Global Formulation Development Outsourcing market can be segmented by service, formulation, therapeutic area, and by region. Based on the service, the market can be divided into preformulation and formulation development. Based on formulation, the market can be segmented into oral, injectable, topical, and others. Based on therapeutic areas, the market can be differentiated into oncology, infectious disease, neurology, hematology, respiratory, cardiovascular, dermatology, and others.

Market Players

Charles River Laboratories., Aizant Drug Research Solutions Private Limited., Catalent Inc., Laboratory Corporation of America Holdings., Syngene International Ltd., Irisys LLC., Intertek Group PLC., Piramal Pharma Solutions., Quotient Sciences Ltd., Patheon Inc., Emergent BioSolutions Inc, Lonza Group AG are some of the leading players operating in the Global Formulation Development Outsourcing Market.

Report Scope:

In this report, Global Formulation Development Outsourcing market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Formulation Development Outsourcing Market, By Product and Service:

  • Consumables
  • Instruments
  • Services Instruments

Formulation Development Outsourcing Market, By Application:

  • Drug Discovery & Development
  • Clinical Diagnosis
  • Others

Formulation Development Outsourcing Market, By End Use:

  • Pharmaceuticals & Biotechnology Companies
  • Academic Research Institutes
  • Contract Research Organizations
  • Others

Formulation Development Outsourcing Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Formulation Development Outsourcing Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Formulation Development Outsourcing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Service (Preformulation, Formulation Development)
    • 5.2.2. By Formulation (Oral, Injectable, Topical, Others)
    • 5.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others )
    • 5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.5. By Company (2022)
  • 5.3. Market Map
    • 5.3.1 By Service
    • 5.3.2 By Formulation
    • 5.3.3 By Therapeutic Area
    • 5.3.4 By Region

6. North America Formulation Development Outsourcing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Service (Preformulation, Formulation Development)
    • 6.2.2. By Formulation (Oral, Injectable, Topical, Others)
    • 6.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Formulation Development Outsourcing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Service
        • 6.3.1.2.2. By Formulation
        • 6.3.1.2.3. By Therapeutic Area
    • 6.3.2. Canada Formulation Development Outsourcing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Service
        • 6.3.2.2.2. By Formulation
        • 6.3.2.2.3. By Therapeutic Area
    • 6.3.3. Mexico Formulation Development Outsourcing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Service
        • 6.3.3.2.2. By Formulation
        • 6.3.3.2.3. By Therapeutic Area

7. Europe Formulation Development Outsourcing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Service (Preformulation, Formulation Development)
    • 7.2.2. By Formulation (Oral, Injectable, Topical, Others)
    • 7.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Formulation Development Outsourcing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Service
        • 7.3.1.2.2. By Formulation
        • 7.3.1.2.3. By Therapeutic Area
    • 7.3.2. Germany Formulation Development Outsourcing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Service
        • 7.3.2.2.2. By Formulation
        • 7.3.2.2.3. By Therapeutic Area
    • 7.3.3. United Kingdom Formulation Development Outsourcing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Service
        • 7.3.3.2.2. By Formulation
        • 7.3.3.2.3. By Therapeutic Area
    • 7.3.4. Italy Formulation Development Outsourcing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Service
        • 7.3.4.2.2. By Formulation
        • 7.3.4.2.3. By Therapeutic Area
    • 7.3.5. Spain Formulation Development Outsourcing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Service
        • 7.3.5.2.2. By Formulation
        • 7.3.5.2.3. By Therapeutic Area

8. Asia-Pacific Formulation Development Outsourcing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Service (Preformulation, Formulation Development)
    • 8.2.2. By Formulation (Oral, Injectable, Topical, Others)
    • 8.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Formulation Development Outsourcing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Service
        • 8.3.1.2.2. By Formulation
        • 8.3.1.2.3. By Therapeutic Area
    • 8.3.2. India Formulation Development Outsourcing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Service
        • 8.3.2.2.2. By Formulation
        • 8.3.2.2.3. By Therapeutic Area
    • 8.3.3. Japan Formulation Development Outsourcing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Service
        • 8.3.3.2.2. By Formulation
        • 8.3.3.2.3. By Therapeutic Area
    • 8.3.4. South Korea Formulation Development Outsourcing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Service
        • 8.3.4.2.2. By Formulation
        • 8.3.4.2.3. By Therapeutic Area
    • 8.3.5. Australia Formulation Development Outsourcing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Service
        • 8.3.5.2.2. By Formulation
        • 8.3.5.2.3. By Therapeutic Area

9. South America Formulation Development Outsourcing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Service (Preformulation, Formulation Development)
    • 9.2.2. By Formulation (Oral, Injectable, Topical, Others)
    • 9.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Formulation Development Outsourcing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Service
        • 9.3.1.2.2. By Formulation
        • 9.3.1.2.3. By Therapeutic Area
    • 9.3.2. Argentina Formulation Development Outsourcing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Service
        • 9.3.2.2.2. By Formulation
        • 9.3.2.2.3. By Therapeutic Area
    • 9.3.3. Colombia Formulation Development Outsourcing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Service
        • 9.3.3.2.2. By Formulation
        • 9.3.3.2.3. By Therapeutic Area

10. Middle East and Africa Formulation Development Outsourcing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Service (Preformulation, Formulation Development)
    • 10.2.2. By Formulation (Oral, Injectable, Topical, Others)
    • 10.2.3. By Therapeutic Area (Oncology, Infectious Disease, Neurology, Hematology, Respiratory, Cardiovascular, Dermatology, Others)
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Formulation Development Outsourcing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Service
        • 10.3.1.2.2. By Formulation
        • 10.3.1.2.3. By Therapeutic Area
    • 10.3.2. Saudi Arabia Formulation Development Outsourcing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Service
        • 10.3.2.2.2. By Formulation
        • 10.3.2.2.3. By Therapeutic Area
    • 10.3.3. UAE Formulation Development Outsourcing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Service
        • 10.3.3.2.2. By Formulation
        • 10.3.3.2.3. By Therapeutic Area

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Global Formulation Development Outsourcing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Product Offerings
  • 15.3. Recent Developments
  • 15.4. Financials (As Reported)
  • 15.5. Key Personnel
  • 15.6. SWOT Analysis
    • 15.6.1 Charles River Laboratories.
    • 15.6.2 Aizant Drug Research Solutions Private Limited.
    • 15.6.3 Catalent Inc.
    • 15.6.4 Laboratory Corporation of America Holdings.
    • 15.6.5 Syngene International Ltd.
    • 15.6.6 Irisys LLC.
    • 15.6.7 Intertek Group PLC.
    • 15.6.8 Piramal Pharma Solutions.
    • 15.6.9 Qiotient Sciences Ltd.
    • 15.6.10 Patheon Inc.
    • 15.6.11 Emergent BioSolutions Inc
    • 15.6.12 Lonza Group AG

16. Strategic Recommendations